Skip to content

Autologous Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis

Efficacy of Autologous Micro-fragmented Adipose Tissue Intra-articular Injection for Knee Osteoarthritis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03788265
Enrollment
60
Registered
2018-12-27
Start date
2016-01-01
Completion date
2021-01-01
Last updated
2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Brief summary

Knee osteoarthritis (OA) is characterized by loss of cartilage leading to instability, reduced range of motion, and functional limitations. Current treatment has various limitations so that alternative options to restore function and alleviate joint pain, with the ultimate goal of healing damaged articular cartilage are needed. Mesenchymal stem cells (MSCs) therapy has shown promising results. However, MSCs are limited by complex regulatory issues. Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue through mild mechanical force. This procedure is enzyme free and requires no clonal expansion or manipulation. The goal of this study is to evaluate the possible benefits of reduced joint pain and increased joint functionality in patients with knee osteoarthritis after the injection of Lipogems.

Interventions

DEVICELipogems

harvest and inject micro-fragment adipose tissue

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age of eighteen or older * Diagnosis of symptomatic knee osteoarthritis * Radiographic evidence of knee osteoarthritis * Failure of conservative treatment

Exclusion criteria

* Treatment with any intra-articular knee injection within 8 weeks before surgery * Any disease or condition potential to interfere study outcome * Under 18 years of age

Design outcomes

Primary

MeasureTime frameDescription
Change in Visual Analog Pain Scale (VAS) Over TimePre-op, then post-op: 1 month, 3 months, 6 months, 1 year, 2 yearsScaled pain score to assess change in a patient's knee pain over time. Pain level is marked on a 100 mm line with the 0 mm corresponding to no pain and the 100 mm corresponding to 10/10 pain. Using a ruler, the score is determined by measuring the distance (mm) on the 100 mm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100. The following cut points on the pain VAS have been recommended: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).

Secondary

MeasureTime frameDescription
Change in the knee injury and osteoarthritis score (KOOS) Over TimePre-op, then post-op: 1 month, 3 months, 6 months, 1 year, 2 yearsPatient self-reported outcome measure to assess the patient's opinion about their knee and associated issues. KOOS consists of 5 subscales; Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL). Standardized answer options are given (5 Likert boxes) and each question gets a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated by adding the subscales together.

Countries

China

Contacts

Primary ContactXuesong Dai, MD., PhD
+8687783777

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026